Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cytoreductive nephrectomy in metastatic kidney cancer

what do we do now?

Kokorovic, Andrea; Rendon, Ricardo A.

Current Opinion in Supportive and Palliative Care: September 2019 - Volume 13 - Issue 3 - p 255–261
doi: 10.1097/SPC.0000000000000433
RENAL AND UROLOGICAL PROBLEMS: Edited by Fred Saad
Buy

Purpose of review Metastatic renal cell carcinoma (mRCC) has traditionally been treated with a combination of targeted systemic therapy and cytoreductive nephrectomy. This approach has recently become a topic of debate, because of new randomized data suggesting a lack of survival benefit for cytoreductive nephrectomy. We review the literature relevant to cytoreductive nephrectomy in the modern era of targeted and immune systemic therapy, and discuss the ongoing role of surgery for treatment of patients with mRCC.

Recent findings Randomized trials in the cytokine era of systemic therapy for mRCC demonstrated a survival benefit to cytoreductive nephrectomy, which led to its widespread adoption. There is overwhelming support in favor of cytoreductive nephrectomy from large studies using retrospective data in the targeted therapy era. A recent randomized control trial (CARMENA) failed to show superiority of cytoreductive nephrectomy in combination with sunitinib, versus sunitinib alone with respect to overall survival. The trial had major limitations including selection of many poor-risk patients, which we know do not benefit from surgery. The results of CARMENA should lead to the abandonment of cytoreductive nephrectomy in poor-risk and many intermediate-risk patients with mRCC. However, there is a knowledge gap with respect to the role of cytoreductive nephrectomy in patients with good risk disease, and we argue that these patients should be strongly considered for cytoreductive nephrectomy.

Summary Cytoreductive nephrectomy continues to play an important role in the multidisciplinary management of mRCC; however, diligent patient selection is crucial, as only patients with good risk features are likely to derive benefit from surgery.

Department of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Correspondence to Ricardo A. Rendon, Department of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Room 210, 5-South, Victoria Building, 1276 South Park St, Halifax, NS, Canada B3H 2Y9. Tel: +1 902 473 6604; fax: +1 902 492 2437; e-mail: rrendon@dal.ca

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.